Finally,an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon

Abstract

Objective

Coronavirus disease 2019 (COVID-19) is a respiratory infection known as severe respiratory acute syndrome coronavirus 2 (SARS-CoV-2). The purpose of this manuscript is to review information leading to the Food and Drug Administration (FDA) approval of the Pfizer-BioNTech COVID-19 Vaccine.

Data Sources

A literature search was conducted of PubMed and clinicaltrials.gov (August 2018—October 2021) to identify trials related to the FDA approval of Pfizer-BioNTech COVID-19 Vaccine.

Study selection and data extraction

Trials included are those the FDA deemed significant and accurate enough to be included in the FDA approval process. Information not recognized by the Centers of Disease Control and Prevention (CDC) nor FDA is omitted to not add to further confusion and misinformation.

Data synthesis

In persons 16 years or older without evidence of prior SARS-CoV-2 infection, a total of 77 COVID-19 cases (0.39%) in the vaccine group from 7 days onward after the second dose vs 833 (4.1%) in the placebo group (Vaccine efficacy 91.1%; 95% confidence interval [CI]: 88.8-93.1). According the CDC definition of severe infection, there were no severe infections in the vaccine group 7 days and onward after the second dose, compared to 31 (0.15%) in the placebo group (Vaccine efficacy 100%; 95% CI: 87.6-100.0). Relevance to Patient Care and Clinical Practice: Reduction of infection by SARS-COV-2 is a top priority in protecting the health of all people and the official approval of the Pfizer-BioNTech vaccination may improve this goal.

Conclusions

Data available show a high efficacy rate of preventing SARS -CoV-2 with relatively low rates of ADE after full vaccination with Pfizer-BioNTech COVID-19 vaccine.

Keywords

COVID-19 SARS-CoV-19 Pfizer-BioNTech COVID-19 vaccine

Get full access to this article

View all access options for this article.

References

Coronavirus disease (COVID-19). Geneva, Switzerland: World Health Organization; 2021. https://www.who.int/health-topics/coronavirus#tab=tab_1.

Coronavirus disease (COVID-19). Rochester, MN: World Health Organization; 2021. https://www.mayoclinic.org/diseases-conditions/coronavirus/symptoms-causes/syc-20479963.

COVID data tracker. Atlanta, GA: Centers for Disease Control and Prevention; 2021. https://covid.cdc.gov/covid-data-tracker/#datatracker-home.

WHO coronavirus (COVID-19) dashboard. Geneva, Switzerland: World Health Organization; 2021. https://covid19.who.int/.

Delta variant: what we know about the science. Atlanta, GA: Centers for Disease Control and Prevention; 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html.

Van Doremalen

Bushmaker

Morris

, et al. Aerosol and surface stability of HCoV-19 (SAR-CoV-2) compared to SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567. doi:10.1056/NEJMc2004973.

Coronavirus (COVID-19) update: FDA issues authorization for first molecular non-prescription, at-home test. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-authorization-first-molecular-non-prescription-home-test.

Clinical pharmacology. Tampa, FL: Gold Standard Inc.; 2006. http://cp.gsm.com.

Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19.

10.

Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19#:~:text=Today%2C%20the%20U.S.%20Food%20and,oxygen%2C%20non%2Dinvasive%20or%20invasive.

11.

FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19.

12.

Moderna COVID-19 vaccine. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.

13.

Janssen COVID-19 vaccine. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine.

14.

FDA approves first COVID-19 vaccine. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

15.

Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised.

16.

Cominarty (COVID-19 vaccine, mRNA). New York, NY: Pfizer Inc.; 2021.

17.

BioNTech SE. A trial investigating the safety and effects of four BNT162 vaccines against COVID-2019 in healthy and immunocompromised adults. Accessed September 7, 2021. https://clinicaltrials.gov/ct2/show/study/NCT04380701.

18.

BioNTech SE. Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. Accessed September 7, 2021. https://clinicaltrials.gov/ct2/show/NCT04368728.

19.

New CDC data: COVID-19 vaccination safe for pregnant people. CDC Online Newsroom. Centers for Disease Control and Prevention. Accessed October 9, 2021. https://www.cdc.gov/media/releases/2021/s0811-vaccine-safe-pregnant.html.

20.

Breastfeeding and caring for newborns if you have COVID-19. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases (NCIRD). Accessed October 9, 2021. https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/pregnancy-breastfeeding.html.

21.

Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.

22.

Kamar

Abravanel

Marion

, et al. Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662. doi:10.1056/NEJMc2108861.

23.

Learn more about COVID-19 vaccines from the FDA: learn about the evidence supporting FDA-approval of Comirnaty and FDA emergency use authorization of COVID-19 vaccines. https://www.fda.gov/consumers/consumer-updates/learn-more-about-covid-19-vaccines-fda.

24.

Bernal

Andrews

Gower

, et al. Effectiveness of covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891.

25.

Krause

Fleming

Peto

, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398:1377–1380. doi:10.1016/S0140-6736(21)02046-8.

26.

FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. Silver Spring, MD: U.S. Food and Drug Administration; 2021. https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations.

27.

Shimabukuro

Kim

Myers

, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384:2273–2282. doi:10.1056/NEJMoa2104983.

28.

Pfizer and BioNTech announce positive topline results from pivotal trial of covid-19 vaccine in children 5 to 11 years. New York, NY: Pfizer Inc.; 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results.